News | February 12, 2010

MITA Writes Prescription for Lowering Radiation Dose

February 12, 2010 - After the U.S. FDA announced it is launching a program designed to reduce unnecessary medical radiation exposure with a focus on computed tomography, nuclear medicine and fluoroscopy, the Medical Imaging & Technology Alliance (MITA) gave its prescription for lowering radiation.

MITA, an association representing the manufacturers, innovators and developers of medical imaging and radiation therapy systems, endorsed eight key principles to reduce exposure to unnecessary medical radiation, further minimize medical errors and improve reporting of adverse events.

“Over the past 20 years, innovations by imaging manufacturers have reduced radiation for many procedures by up to 75 percent,” said Dave Fisher, executive director of MITA. “MITA and its member companies look forward to working with all who are involved in patients’ continuum of care to reduce medical radiation, reduce the number of medical errors and enhance transparency and timeliness of error reporting while also continually improving technology to aid physicians in turning patients into survivors.”

To that end, MITA endorses:

• Expanding and integrating appropriateness criteria into physician decision-making.

• Creating a national dosage registry to ensure longitudinal tracking of dose levels for patients across America.

• Adopting a standardized method of storing of diagnostic imaging and radiation therapy information within electronic health records.

• Expanding mandatory accreditation for advanced imaging facilities.

• Establishing minimum standards for training and education for hospital and imaging facility personnel who perform medical imaging exams and deliver radiation therapy treatments.

• Develop enhanced operational safety procedures and checklists to reduce medical errors.

• Expanding and standardizing the reporting of medical errors associated with medical radiation across stakeholders in a manner that is transparent for patients, families and physicians.

• Working with stakeholders to develop radiation dose reference values to provide a data point to compare the dose level of a specific procedure. MITA commits to working with other stakeholders to develop the most appropriate way to incorporate this information into manufacturers’ technology.

Proclaimed by the New England Journal of Medicine as one of the top “developments that changed the face of clinical medicine” during the last millennium, medical imaging and radiation therapy have revolutionized health care delivery in America. In a recent Dartmouth-Stanford Survey of Medical Innovations, leading general internists concurred ranking MRI and CT technology as the most valuable medical innovation in the last 30 years. Likewise, radiation therapy has become the standard of care for treating most types of cancer. Radiation therapy offers highly personalized, noninvasive and cost-effective care for up to 60 percent of all diagnosed cancer patients in the United States.

MITA and its members have a long history of supporting the reduction in radiation dose. MITA’s members incorporate the radiation dose management and optimization principle, as low as reasonably achievable (ALARA), into all imaging procedures and technologies. In addition, MITA has collaborated with all medical community stakeholders in the in the Image Gently campaign to develop protocols specifically for children to optimize scan protocols, as well as on scanner calibrations using pediatric specific phantoms for improved image quality.

MITA also convened a stakeholders meeting in November including physicians, physicists, industry and Food and Drug Administration officials to discuss ways to prevent future medical errors that involve radiation. MITA is also co-sponsoring an upcoming radiation dose summit to further the education of providers and physicists on the new technologies our companies manufacture.

For more information: www.medicalimaging.org

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Computer-Aided Detection Software | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
Baylor Scott White Heart Hospital Siemens Flash CT system used for dedicated cardiac CT scans, CCTA, CTA.
360 Photos | CT Angiography (CTA) | May 20, 2019
This is a 360 degree photo of a Siemens Somatom Force 64-slice, dual-source computed tomography (CT) system installed
360 Photos | Angiography | May 17, 2019
This is a view inside one of the 11 cath labs at ...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
FDA Clears Aidoc's AI Solution for Flagging Pulmonary Embolism
Technology | Artificial Intelligence | May 15, 2019
Artificial intelligence (AI) solutions provider Aidoc has been granted U.S. Food and Drug Administration (FDA)...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...